Pulmonary Arterial Hypertension (PAH) | Norton Healthcare

Indication: Pulmonary Arterial Hypertension (PAH)

A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg

Sub-indication: Pulmonary Arterial Hypertension (PAH)

Study Type: Drug Study

Principal Investigator: John McConnell, M.D.
Norton Pulmonary Specialists

Sponsor: Sponsor: Actelion/Janssen

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.